巴西 IBD 私人患者的感染率(肺结核):随访 15 年。

Q2 Medicine
Arquivos de Gastroenterologia Pub Date : 2024-03-15 eCollection Date: 2024-01-01 DOI:10.1590/S0004-2803.24612023-148
Didia B Cury, Liana C B Cury, Ana C Micheletti, Rogério A Oliveira, José J S Gonçalves
{"title":"巴西 IBD 私人患者的感染率(肺结核):随访 15 年。","authors":"Didia B Cury, Liana C B Cury, Ana C Micheletti, Rogério A Oliveira, José J S Gonçalves","doi":"10.1590/S0004-2803.24612023-148","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Latent tuberculosis (LTB) is a condition where the patient is infected with Mycobacterium tuberculosis but does not develop active TB. There's a possibility of tuberculosis (TB) activation following the introduction of anti-TNFs.</p><p><strong>Objective: </strong>To assess the risk of biological therapy inducing LTB during inflammatory bowel diseases (IBD) treatment over 15 years in a high-risk area in Brazil.</p><p><strong>Methods: </strong>A retrospective study of an IBD patients' database was carried out in a private reference clinic in Brazil. All patients underwent TST testing and chest X-ray prior to treatment, and once a year after starting it. Patients were classified according to the Montreal stratification and risk factors were considered for developing TB.</p><p><strong>Results: </strong>Among the analyzed factors, age and gender were risk factors for LTB. DC (B2 and P) and UC (E2) patients showed a higher number of LTB cases with statistical significance, what was also observed for adalimumab and infliximab users, compared to other medications, and time of exposure to them favored it significantly. Other factors such as enclosed working environment have been reported as risk.</p><p><strong>Conclusion: </strong>The risk of biological therapy causing LTB is real, so patients with IBD should be continually monitored. This study reveals that the longer the exposure to anti-TNFs, the greater the risk.</p><p><strong>Background: </strong>•Rate of infection (tuberculosis) in Brazilians IBD private patients: follow-up 15 years.</p><p><strong>Background: </strong>•Patients treated with immunosuppressants and/or anti-TNFs have a higher risk of developing opportunistic infections, among them the most common is latent tuberculosis or even active tuberculosis.</p><p><strong>Background: </strong>•Similar risks may be noted in patients with inflammatory bowel diseases (IBDs).</p><p><strong>Background: </strong>•This study reveals that the longer the exposure to anti-TNFs, the greater the risk for de IBD patients.</p><p><strong>Background: </strong>•The study demonstrated the importance of monitoring these patients permanently and continuously.</p>","PeriodicalId":35671,"journal":{"name":"Arquivos de Gastroenterologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RATE OF INFECTION (TUBERCULOSIS) IN BRAZILIANS IBD PRIVATE PATIENTS: FOLLOW-UP 15 YEARS.\",\"authors\":\"Didia B Cury, Liana C B Cury, Ana C Micheletti, Rogério A Oliveira, José J S Gonçalves\",\"doi\":\"10.1590/S0004-2803.24612023-148\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Latent tuberculosis (LTB) is a condition where the patient is infected with Mycobacterium tuberculosis but does not develop active TB. There's a possibility of tuberculosis (TB) activation following the introduction of anti-TNFs.</p><p><strong>Objective: </strong>To assess the risk of biological therapy inducing LTB during inflammatory bowel diseases (IBD) treatment over 15 years in a high-risk area in Brazil.</p><p><strong>Methods: </strong>A retrospective study of an IBD patients' database was carried out in a private reference clinic in Brazil. All patients underwent TST testing and chest X-ray prior to treatment, and once a year after starting it. Patients were classified according to the Montreal stratification and risk factors were considered for developing TB.</p><p><strong>Results: </strong>Among the analyzed factors, age and gender were risk factors for LTB. DC (B2 and P) and UC (E2) patients showed a higher number of LTB cases with statistical significance, what was also observed for adalimumab and infliximab users, compared to other medications, and time of exposure to them favored it significantly. Other factors such as enclosed working environment have been reported as risk.</p><p><strong>Conclusion: </strong>The risk of biological therapy causing LTB is real, so patients with IBD should be continually monitored. This study reveals that the longer the exposure to anti-TNFs, the greater the risk.</p><p><strong>Background: </strong>•Rate of infection (tuberculosis) in Brazilians IBD private patients: follow-up 15 years.</p><p><strong>Background: </strong>•Patients treated with immunosuppressants and/or anti-TNFs have a higher risk of developing opportunistic infections, among them the most common is latent tuberculosis or even active tuberculosis.</p><p><strong>Background: </strong>•Similar risks may be noted in patients with inflammatory bowel diseases (IBDs).</p><p><strong>Background: </strong>•This study reveals that the longer the exposure to anti-TNFs, the greater the risk for de IBD patients.</p><p><strong>Background: </strong>•The study demonstrated the importance of monitoring these patients permanently and continuously.</p>\",\"PeriodicalId\":35671,\"journal\":{\"name\":\"Arquivos de Gastroenterologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arquivos de Gastroenterologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1590/S0004-2803.24612023-148\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arquivos de Gastroenterologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/S0004-2803.24612023-148","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:潜伏结核病(LTB)是指患者感染了结核分枝杆菌但未发展为活动性结核病。在使用抗肿瘤坏死因子(anti-TNFs)后,结核病(TB)有可能被激活:评估巴西一个高风险地区 15 年来炎症性肠病(IBD)治疗期间生物疗法诱发 LTB 的风险:巴西一家私人参考诊所对 IBD 患者数据库进行了一项回顾性研究。所有患者在接受治疗前均接受了 TST 检测和胸部 X 光检查,并在开始治疗后每年接受一次检查。根据蒙特利尔分层法对患者进行了分类,并考虑了患结核病的风险因素:在分析的因素中,年龄和性别是导致肺结核的危险因素。与其他药物相比,DC(B2和P)和UC(E2)患者的LTB病例数较高,且有统计学意义,阿达木单抗和英夫利昔单抗使用者也观察到了这一点,而接触这些药物的时间则明显有利于LTB的发生。其他因素,如封闭的工作环境,也被报告为风险因素:结论:生物疗法导致低密度脂蛋白血症的风险是真实存在的,因此应持续监测 IBD 患者。本研究显示,接触抗肿瘤坏死因子的时间越长,风险越大:-巴西IBD私人患者的感染(结核病)率:随访15年:-使用免疫抑制剂和/或抗-TNFs治疗的患者发生机会性感染的风险较高,其中最常见的是潜伏结核病甚至活动性结核病:-在炎症性肠病(IBD)患者中也可能存在类似风险:-这项研究显示,IBD患者接触抗肿瘤坏死因子的时间越长,风险就越大:-这项研究表明,对这些患者进行长期、持续的监测非常重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
RATE OF INFECTION (TUBERCULOSIS) IN BRAZILIANS IBD PRIVATE PATIENTS: FOLLOW-UP 15 YEARS.

Background: Latent tuberculosis (LTB) is a condition where the patient is infected with Mycobacterium tuberculosis but does not develop active TB. There's a possibility of tuberculosis (TB) activation following the introduction of anti-TNFs.

Objective: To assess the risk of biological therapy inducing LTB during inflammatory bowel diseases (IBD) treatment over 15 years in a high-risk area in Brazil.

Methods: A retrospective study of an IBD patients' database was carried out in a private reference clinic in Brazil. All patients underwent TST testing and chest X-ray prior to treatment, and once a year after starting it. Patients were classified according to the Montreal stratification and risk factors were considered for developing TB.

Results: Among the analyzed factors, age and gender were risk factors for LTB. DC (B2 and P) and UC (E2) patients showed a higher number of LTB cases with statistical significance, what was also observed for adalimumab and infliximab users, compared to other medications, and time of exposure to them favored it significantly. Other factors such as enclosed working environment have been reported as risk.

Conclusion: The risk of biological therapy causing LTB is real, so patients with IBD should be continually monitored. This study reveals that the longer the exposure to anti-TNFs, the greater the risk.

Background: •Rate of infection (tuberculosis) in Brazilians IBD private patients: follow-up 15 years.

Background: •Patients treated with immunosuppressants and/or anti-TNFs have a higher risk of developing opportunistic infections, among them the most common is latent tuberculosis or even active tuberculosis.

Background: •Similar risks may be noted in patients with inflammatory bowel diseases (IBDs).

Background: •This study reveals that the longer the exposure to anti-TNFs, the greater the risk for de IBD patients.

Background: •The study demonstrated the importance of monitoring these patients permanently and continuously.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Arquivos de Gastroenterologia
Arquivos de Gastroenterologia Medicine-Gastroenterology
CiteScore
2.00
自引率
0.00%
发文量
109
审稿时长
9 weeks
期刊介绍: The journal Arquivos de Gastroenterologia (Archives of Gastroenterology), a quarterly journal, is the Official Publication of the Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia IBEPEGE (Brazilian Institute for Studies and Research in Gastroenterology), Colégio Brasileiro de Cirurgia Digestiva - CBCD (Brazilian College of Digestive Surgery) and of the Sociedade Brasileira de Motilidade Digestiva - SBMD (Brazilian Digestive Motility Society). It is dedicated to the publishing of scientific papers by national and foreign researchers who are in agreement with the aim of the journal as well as with its editorial policies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信